Deregulation of glucose and lipid metabolism in peripheral tissues is a hallmark of type 2 diabetes. AMP- activated protein kinase (AMPK) is a master regulator of cellular and organismal metabolism which acts as sensor of cellular energy status and plays key roles in glucose and lipid homeostasis in metabolic tissues. AMPK is activated by low nutrients, exercise, adipokines such adiponectin, and by the widely used diabetes therapeutic metformin. Upon activation in liver, AMPK functions to reduce gluconeogenesis and lipogenesis through incompletely understood mechanisms. Previously, the serine/threonine kinase LKB1 was identified as the critical upstream kinase mediating AMPK activation in most mammalian tissues. Genetic deletion of LKB1 in the liver of adult mice resulted in complete loss of hepatic AMPK activity and significant increases in gluconeogenesis and hepatic lipid accumulation, while attenuating the ability of metformin to lower blood glucose. A major challenge in the field remained in decoding the molecular mechanisms through which LKB1-AMPK signaling controls metabolism. Over the past 4 years of this funding, my laboratory performed a multi-pronged screen for direct substrates of AMPK, which led to the identification and study of a number of novel AMPK substrates critical in metabolism, including Raptor, ULK1, Cry1, Srebp1, and HDACs4, 5, and 7. In this first renewal, it is proposed to further dissect the role of AMPK and related kinases in control of glucose metabolism and the therapeutic action of metformin. Given the recent advances in decoding the molecular effectors of the LKB1/AMPK signaling pathway, the relative contributions of different AMPK substrates to metabolic control and metformin's therapeutic action can now begin to be delineated.
In Aim 1, the role of AMPKalpha1, AMPKalpha2, and the related SIK kinases will be compared in control of hepatic glucose metabolism using novel temporally controlled genetic mouse models.
In Aim 2, we will utilize these models to define the relative requirement for LKB1 and AMPK isoforms in the therapeutic action of metformin in liver. A key aspect of this aim is a collaboration with Dr. Davi Wasserman at Vanderbilt University to define the effect of LKB1 and AMPK on metabolic flux in these models. Finally, in the Aim 3, we will expand on our recent discoveries by directly examining the relative roles of Class IIa HDAC-FOXO axis versus CRTC coactivators-CREB axis in the control of glucose homeostasis in liver. These studies disecting the role of the LKB1- AMPK pathway in liver will increase the understanding of how existing widely used diabetes modalities work, and identify critical new targets for future type 2 diabetes therapeutics.

Public Health Relevance

Despite the fact metformin is the most widely used type 2 diabetes therapeutic in the world (>100 million users estimated), little is known about its mechanism of action. The proposed studies aim at determining how critical the activation of the AMPK signaling pathway by metformin is to this drug's action, and to decode which downstream AMPK substrates are critical for its beneficial effects on glucose and lipid metabolism. The proposed studies on how this key biochemical signaling pathway activated by metformin regulates glucose metabolism will increase our understanding of how this current modality works and will identify many additional targets for the next generation of type 2 diabetes therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK080425-07
Application #
8492075
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Pawlyk, Aaron
Project Start
2007-09-30
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
7
Fiscal Year
2013
Total Cost
$449,305
Indirect Cost
$215,292
Name
Salk Institute for Biological Studies
Department
Type
DUNS #
078731668
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Mouchiroud, Laurent; Eichner, Lillian J; Shaw, Reuben J et al. (2014) Transcriptional coregulators: fine-tuning metabolism. Cell Metab 20:26-40
Luan, Bing; Goodarzi, Mark O; Phillips, Naomi G et al. (2014) Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4. Cell Metab 19:1058-65
Mihaylova, Maria M; Shaw, Reuben J (2013) Metabolic reprogramming by class I and II histone deacetylases. Trends Endocrinol Metab 24:48-57
Shackelford, David B; Abt, Evan; Gerken, Laurie et al. (2013) LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23:143-58
Mihaylova, Maria M; Shaw, Reuben J (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13:1016-23
Mihaylova, Maria M; Vasquez, Debbie S; Ravnskjaer, Kim et al. (2011) Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145:607-21
Mair, William; Morantte, Ianessa; Rodrigues, Ana P C et al. (2011) Lifespan extension induced by AMPK and calcineurin is mediated by CRTC-1 and CREB. Nature 470:404-8
Li, Yu; Xu, Shanqin; Mihaylova, Maria M et al. (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13:376-88
Egan, Daniel F; Shackelford, David B; Mihaylova, Maria M et al. (2011) Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331:456-61
Wang, Biao; Moya, Noel; Niessen, Sherry et al. (2011) A hormone-dependent module regulating energy balance. Cell 145:596-606

Showing the most recent 10 out of 18 publications